BTK and B-cell chronic lymphocytic leukemia: Ibrutinib inhibits BTK by binding covalently to the cysteine 481 (C481) residue of BTK to block phosphorylation and downstream B-cell receptor signaling, critical for the survival of many B-cell malignancies like CLL [34].